<span item_type="fundamental" item_id="8acac5c117961cc825b9ae5a7c7e91cc" counter_id="ST/US/ALLK" env="prod"></span><span item_type="announcement" item_id="513564801449920001" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.29, meeting the estimate of USD -0.29.</p><p></p><h3>Segment Revenue</h3><ul><li>Allakos Inc. did not generate any revenue during the three months ended March 31, 2025, as the company is a clinical stage biotechnology firm focused on research and development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $26.2 million for the three months ended March 31, 2025, compared to a net loss of $71.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li><li><strong>Total Operating Expenses</strong>: Operating expenses decreased to $26.7 million for the three months ended March 31, 2025, from $73.1 million for the same period in 2024, primarily due to reduced research and development expenses and the absence of impairment charges in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li><li><strong>Research and Development Expenses</strong>: These expenses were $13.5 million for the three months ended March 31, 2025, a decrease from $34.8 million in the same period in 2024, due to lower manufacturing and clinical spending.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses increased to $13.2 million for the three months ended March 31, 2025, from $10.9 million in the same period in 2024, primarily due to costs associated with exiting the San Carlos facility.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: The company used $28.4 million in net cash for operating activities during the three months ended March 31, 2025, compared to $32.5 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: The company generated $33.4 million from investing activities during the three months ended March 31, 2025, primarily from the sale and maturities of investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Impairment of Long-Lived Assets</strong>: No impairment charges were recognized during the three months ended March 31, 2025, compared to $27.3 million in charges during the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Allakos Inc. is exploring strategic alternatives to maximize stockholder value, including a merger, sale, or other strategic transaction, following the discontinuation of its AK006 product candidate.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Merger Agreement with Concentra Biosciences, LLC, which includes a cash tender offer for all outstanding shares of Allakos Inc. common stock at $0.33 per share. The merger is expected to close in May 2025, subject to various conditions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm"></span></li></ul>

Allakos | 10-Q: FY2025 Q1 EPS Meets Estimate at USD -0.29